The primary endpoint reached this time is a single-arm, open, multiple-arm, open-ended, multiple-arm, open-ended, multiple-arm, unresectable or metastatic MSI-H or dMMR solid tumor patient who has failed standard treatments to evaluate the efficacy, safety, and tolerability of HLX10.
Drug: Cereblon E3 ligase modulatorResearch and development company: Bristol-Myers Squibb/XinjiTreatment of diseases: Acute myeloid leukemia (AML)Introduction: Cereblon E3 ligase modulator has immunomodulatory and pro-apoptotic activities.
S. FDA has accelerated its approval of its Trop-2 antibody conjugate drug Trodelvy (sacituzumab govitecan-hziy) to expand the scope of use for local treatment Patients with advanced or metastatic urothelial cancer.
S. FDA has accelerated the approval of its Trop-2 antibody conjugate drug Trodelvy (sacituzumab govitecan-hziy) to expand its scope of use for the treatment of locally advanced or metastatic urothelium Cancer patients.
The source of this page with content of products and services is from Internet,
which doesn't represent Echemi's opinion. If you have any queries, please write
to email@example.com. It will be replied within 5 days.
Moreover, if you find any instances of plagiarism from the page,
please send email to firstname.lastname@example.org with relevant evidence.